Form 4: CONMED Corp Executive Stanley W. Peters III Reports Stock Option Grant

Stanley W. Peters III, President AS and AET of CONMED Corp, reports the acquisition of 33,508 stock options on March 1, 2024.

Summary

• On March 1, 2024, Stanley W. Peters III, President AS and AET of CONMED Corp, reported the acquisition of 33,508 stock options.
• The options, with an exercise price of $79.95, were granted under the company's 2018 Long-Term Incentive Plan.
• The options generally vest in equal amounts over a five-year period and expire on March 1, 2034.
• Following the transaction, Peters directly owns 33,508 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning executive incentives with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in the medical technology sector.
• Companies like Stryker (SYK), Medtronic (MDT), and Boston Scientific (BSX) also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is fairly typical, designed to retain key personnel and incentivize long-term value creation.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially leading to increased shareholder value.

Key Dates